ArticleJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine2026
Ultrasound-Guided Iodine-125 Seed Implantation for Cervical Metastatic Lymph Nodes: An Analysis of Efficacy and Safety.
Article in Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the efficacy and safety of ultrasound-guided radioactive iodine-125 (
methodsWe conducted a retrospective analysis of 29 patients (with a total of 53 metastatic lymph nodes) who underwent the procedure between January 2021 and December 2023. Under ultrasound guidance,
resultsAll procedures were technically successful. Over a mean follow-up of 15 ± 10.5 months (range: 7-26). Local tumor control rates were 90.5%, 91.1%, and 75.9% at 3, 6, and 12 months, respectively. The 1-year and 2-year overall survival rates for patients were 55.2% and 37.9%; however, these results should be interpreted cautiously due to the small sample size and heterogeneity of primary tumors. The complication profile was favorable, with only one case (3.4%) of skin injury; other adverse events were minor and manageable.
conclusionUltrasound-guided
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.